Home › Trials › NCT07441785
Clinical trial Recruiting at 1 site Observational Ages 18 and up

Immediate and functional outcomes after different reconstructions following proximal stomach removal

Official title: Immediate and Functional Results of Different Types of Reconstructions After Proximal Gastrectomy For Gastric and Esophagogastric Junction Cancer

Run by P. Herzen Moscow Oncology Research Institute · NCT07441785 · Data updated 2026-11-12

This project will compare different ways of reconnecting the digestive tract after proximal gastrectomy to see which approach leads to better function and quality of life for people having surgery for cancers at the top of the stomach or the esophagogastric junction.

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment400 (estimated)
SponsorP. Herzen Moscow Oncology Research Institute
Government
Locations1 site (Moscow)
StatusRecruiting
StartedJanuary 1, 2025
Main results expectedDecember 31, 2028
Study endsJune 1, 2029
Registry record updatedApril 22, 2026
Trial IDNCT07441785 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults with clinically localized primary gastric cancer or Siewert type II–III esophagogastric junction cancer (cT1-3N0-2M0) scheduled for proximal gastrectomy with curative intent are eligible.

Probably not a fit

Patients with metastatic disease, Siewert type I tumors, emergency or non-curative surgery, prior stomach or colon surgery, synchronous other cancers, or those requiring additional procedures are excluded and unlikely to benefit from these comparisons.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational cohort of consecutive patients undergoing proximal gastrectomy with curative intent at a Moscow oncology center between January 1, 2025 and December 31, 2026, comparing commonly used reconstruction methods (direct esophagogastrostomy variants, double-tract, jejunal interposition, and anti-reflux anastomoses). Clinical and functional endpoints will include immediate postoperative morbidity and mortality, reflux esophagitis, food passage problems, dumping symptoms, nutritional changes, and patient-reported quality of life. Data will be collected prospectively after open, laparoscopic, or robotic procedures and analyzed to identify patterns of benefit and harm across techniques. The goal is to provide systematic, comparative functional outcome data to inform surgical decision-making and standardize care regionally.

Why it matters

Potential benefit: If successful, the findings could identify reconstruction methods that reduce reflux and nutritional problems and improve quality of life after proximal gastrectomy.

How similar studies have gone: Small series and single-center reports suggest some anti-reflux and double-tract techniques can reduce reflux and improve function, but there is no large, consistent evidence or consensus on the optimal approach.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* All consecutive patients with clinically documented primary Gastric or Esophagogastric Junction malignancy (including Siewert I and II) cT1-3N0-2M0 undergoing proximal gastrectomy with curative intent - via open, laparoscopic or robotic approach between 01th January 2025 and 31th December 2026

Exclusion Criteria:

* Patients with clinical evidence of metastatic disease, including positive peritoneal cytology on a previous staging laparoscopy, or those with known synchronous other cancers.
* Esophagogastric Junction Siewert I malignancy
* Patients submitted to Emergency surgery or surgery without curative intent
* Patients undergoing any other surgery in addition to the curative surgery for primary Esophageal or Esophagogastric Junction malignancy
* Patients who have previously undergone surgery on the stomach or colon

Where it's running

  • P.Herzen Moscow Oncological Research Institute
    Moscow, Russia     Recruiting

Study contacts

  • Principal investigator: Vladimir Khomyakov, MD, PhD — P.Herzen Moscow Oncological Research Institute
  • Study coordinator: Andrey Ryabov, MD, PhD
  • Email: ryabovdoc@mail.ru
  • Phone: +7 (495) 150-11-22

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Gastric Cancer (GC) 30Siewert Type II Adenocarcinoma of Esophagogastric Junction 4
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.